Ece ONUR, Ferda BİLGİR, Papatya DEGİRMENCİ, Cengiz KİRMAZ

ALLERJİK RİNİTLİ HASTALARDA İMMÜNOTERAPİ ÖNCESİ VE SONRASI FETUİN A DÜZEYLERİNİN KARŞILAŞTIRILMASI

Giriş: Bir serum glikoproteini olan Fetuin-A'nın çeşitli hastalıklardaki rolü farklı çalışmalarda bildirilmiştir. Alerjik hastalıklarda Fetuin A ile ilgili henüz bir çalışma yoktur. Allerjik Rinitte (AR) Fetuin-A'nın rolünü belirlemeyi amaçladık. Gereç ve Yöntemler: Allerjik Riniti olan 18 yaş üstü 30 hasta ve 30 sağlıklı gönüllü çalışmaya alındı. Başlangıç ve altıncı ay serum ve nazal lavaj Fetuin-A düzeyleri ile nazal semptom skorları karşılaştırıldı. Bulgular: AR'li hastaların ortalama Serum Fetuin-A düzeyi 1010.44 ± 679.84mg / L, ortalama nazal Fetuin A düzeyi 946.52 ± 127.123mg / L olarak bulundu. Tedavi sonrası karşılaşılan serum fetuin A (P = 0.046) ve nazal Fetuin A (P

COMPARISON OF FETUIN A LEVELS BEFORE AND AFTER IMMUNOTHERAPY IN PATIENTS WITH ALLERGIC RHINITIS

Introduction: Role of Fetuin-A, a serum glycoprotein, in various diseases has been reported in different studies. There is no available study yet about Fetuin A in allergic diseases. We aimed to determine the role of Fetuin-A in Allergic Rhinitis (AR). Material and Methods: 30 patients aged over 18 and 30 healthy volunteers due to AR were enrolled in the study. Initial and sixth month serum level and nasal lavage Fetuin-A levels as well as nasal symptom scores were compared. Results: Mean Serum Fetuin-A level of patients with AR was found to be 1010.44 ± 679.84mg/L, while mean nasal Fetuin A level was found 946.52 ± 127.123mg/L. The decrease in serum fetuin A (P=0.046) and nasal Fetuin A (P

PDF

___

1. Brożek JL , Bousquet J , Agache I , Agarwal A , BachertC , Bosnic-Anticevich S et al. Allergic rhinitis and its impact on asthma (ARIA) guidelines-2016 Revision J Allergy Clin Immunol 2016; 140 (4); 950-8.
2. Scadding GK, Kariyawasam HH, Scadding G, Mirakian R, Buckley RJ, Dixon T et al. BSACI guideline for the diagnosis and management of allergic and non-allergic rhinitis. Clin Exp Allergy 2017; 47(7): 856–89.
3. Munoz-Cano R, Ribo P, Araujo G, Giralt E, Sanchez-Lopez J, Valero A.Severity of allergic rhinitis impacts sleep and anxiety: results from a large Spanish cohort. Clin Transl Allergy 2018; 8(1): 23.
4. Meltzer EO, Bukstein DA. The economic impact of allergic rhinitis and current guidelines for treatment. Ann Allergy Asthma Immunol 2011; 106(Suppl 2): S12-S6.
5. Schmitt J, Schwarz K, Stadler E, Wustenberg EG. Allergy immunotherapy for allergic rhinitis effectively prevents asthma: Results from a large retrospective cohort study. J Allergy Clin Immunol 2015; 136(6): 1511-6.
6. Diamant Z, Boot JD, Mantzouranis E, Flohr R, Sterk PJ, Gerth van Wijk R. Biyomarkers in asthma and allergic rhinitis. Pulm Pharmacol Ther 2010; 23(6): 468-81.
7. Belkowski SM, Boot JD, Mascelli MA, Diamant Z, de Garavilla L, Hertzog B et al. Cleaved secretory leucocyte protease inhibitör as a biomarker of chymase activity in allergic airway disease. Clin Exp Allergy 2009; 39(8): 1179-86.
8. Shamji MH, Durham SR. Mechanisms of allergen immunotherapy for inhaled allergens and predictive biomarkers. J Allergy Clin Immunol 2017; 140(6): 1485–98.
9. Golden PM, Gleason MM, Togias A. Cysteinil leukotrienes: multifunctional mediators in allergic rhinitis. Clin and Exp Allergy 2006; 36(6): 689-703.
10. Lebreton JP, Joisel F, Raoult JP, Lannuzel B, Rogez JP, Humbert G. Serum concentration of human alpha 2 HS glycoprotein during the inflammatory process: evidence that alpha 2 HS glycoprotein is a negative acute-phase reactant. J Clin Invest 1979; 64(4): 1118-29.
11. Ketteler M, Bongartz P, Westenfeld R, Wildberger JE, Mahnken AH, Böhm R et al. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet 2003; 361(9360): 827-33.
12. Jersman HP, Dransfield I, Hart SP. Fetuin/alpha2-HS glycoprotein enhances phagocytosis of apoptotic cells and macropinocytosis by human macrophages. Clin Sci 2003; 105(3): 273-8.
13. Ciprandi G, Passalacque G. Allergy and the nose. Clin Exp Immunol 2008; 153 (Suppl 1): 22-6.
14. Braunstahl GJ. United airways concept what does it teach us about systemic ınflammation airways disease? Proc Am Thorac Soc 2009; 6(8): 652-4.
15. Lee DKC, Jackson CM, Soutar P, Fardon TC, Lipworth BJ. Effects of single or combined histamine H1-receptor and leucotriene CysLT1-receptor antagonism on nasal adenosine monophosphate challange in persistent allergic rhinitis. Br J Clin Pharmacol 2004; 57(6): 714-9.
16. Roberts G, Pfaar O, Akdis CA, Ansotegui IJ, Durham SR, Gerth van Wijk R et al. EAACI guidelines on allergen immunotherapy: allergic rhinoconjunctivitis. Allergy 2018; 73(4): 765–98.
17. Baena-Cagnani CE, Canonica GW, Zaky Helal M, Gomez RM, Compalati E,Zernotti ME et al. The international survey on the management of allergic rhinitis by physicians and patients (ISMAR). World Allergy Organ J 2015; 8(1): 10.
18. Ketteler M, Bongartz P, Westenfeld R, Wildberger JE, Mahnken AH, Böhm R et al. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet 2003; 361(9360): 827-33.
19. 19. Demetriou M, Binkert C, Sukhu B, Tenenbaum H.C, Dennis J.W. Fetuin/alpha2-HS glycoprotein is a transforming growth factor-beta type II receptor mimic and cytokine antagonist. Journal of Biological Chemistry 1996; 271(22): 12755-61.
20. Szweras M, Liu D, Partridge EA, Pawling J, Sukhu B, Clokie C et al. Alpha2-HS glycoprotein/ fetuin, a transforming growth factor-beta/ bone morphogenetic protein antagonistand remodelling. Journal of Biological Chemistry 2002; 277 (22): 1991-7.
21. Holgate ST. Today’s science-tomorrow’s practise: basic mechanisms of allergy and their clinical implications. Clin Exp All Rev 2002; 2(1): 48-54.
22. Kim TH, Lee SH, Lee HM, Lee SH, Lee SW, Kim WJ et al. Remodelling of nasal mucosa in mild and severe persistent allergic rhinitis with special reference to the distrubution of collagen, proteoglycans and lymphatic vessels. Clin Exp Allergy 2010; 40 (12): 1742-54.
23. Jutel M, Akdiş M, Budak F, Aebischer-Casaulta C, Wrzyszcz M, Blaser Ket al. IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and spesific immunoterapy Eur J Immunol 2003; 33(5): 1205-14.
24. Mori K, Ikari Y, Jono S, Emoto M, Shioi A, Koyama H et al. Fetuin-A is associated withcalcified coronary artery disease. Coron Artery Dis 2010; 21(5): 281-5.
25. Rittig K, Thamer C, Haupt A, Machann J, Peter A, Balletshofer B et al. High plasma fetuin-A is associated with increased carotid intima-media thickness in a middle-aged population. Atherosclerosis 2009; 207(2): 341-2.
26. Stefan N, Fritsche A, Weikert C, Boeing H, Joost HG, Häring HU et al. Plasma fetuin-A levels and the risk of type 2 diabetes. Diabetes 2008; 57(10): 2762-7.
27. Ou HY, Yang YC, Wu HT, Wu JS, Lu FH, Chang CJ. Serum fetuin-A concentrations are elevated in subjects with impaired glucose tolerance and newly diagnosed type 2 diabetes. Clin Endocrinol (Oxf) 2011; 75(4): 450-5.
28. Weikert C, Stefan N, Schulze MB, Pischon T, Berger K, Joost HG et al. Plasma fetuin-a levels and the risk of myocardial infarction and ischemic stroke. Circulation 2008; 118(24): 2555-62.
29. Bilgir O, Kebapcilar L, Bilgir F, Bozkaya G, Yildiz Y, Pinar P et al. Decreased serum fetuin-A levels are associated with coronary artery diseases. Intern Med 2010; 49(13): 1281-5.
30. Pecovnik Balon B, Knehtl M, Bevc S, Jakopin E, Gorenjak M. Fetuin-A as a risk factor for mortality in hemodialysis patients. Wien Klin Wochenschr 2010; 122(Suppl 2): 63-7.
31. Xu Y, Xu M, Bi Y, Song A, Huang Y, Liu Y, et al. Serum fetuin-A is correlated with metabolic syndrome in middle-aged and elderly Chinese. Atherosclerosis 2011; 216(1): 180-6.
32. Brix JM, Stingl H, Höllerl F, Schernthaner GH, Kopp HP, Schernthaner G. Elevated Fetuin-A concentrations in morbid obesity decrease after dramatic weight loss. J Clin Endocrinol Metab 2010; 95(11): 4877-81.
33. Kurt E, Metintaş S, Başyiğit I, Bulut I, Çoşkun E, Dabak S et al.Prevalance and risk factors allergies in Turkey: Results of a multicentric cross-sectional study in adults. Eur Respir J 2009; 33(4): 724-33.
34. Jones N.Allegic rhinitis: etiology, predisposing and risk factors. Rhinology 2004; 42(2): 49-56.